loading page

Remdesivir may not be a magic bullet for COVID-19 from pharmaceutical perspective
  • +1
  • Xiaoxing Huang,
  • Xiuhua Ren,
  • Dong Liu,
  • Zheng He
Xiaoxing Huang
Wuhan University Zhongnan Hospital
Author Profile
Xiuhua Ren
Author Profile

Abstract

Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become the global pandemic and caused hundreds of thousands of people died in the world, which is in urgent need to develop new drug therapy and pathogen progressive information. Although abundant anti-viral drugs has been directly practiced in some patients, there are no specific drug treatment due to the new SARS-CoV-2 virus, which cause great disaster and panic all over the world. Remdesivir has been recently a strong candidate for the treatment of COVID-19. Recently, due to the support of antiviral experiments in vitro and a case report by compassionate use of the drug, remdesivir has been a promising candidate treatment for the treatment of COVID-19. As a broad-spectrum anti-viral compound targeting the viral RNA dependent RNA polymerase, remdesivir has been shown to suppress the coronavirus, such as SARS-CoV and MERS-CoV. However, is remdesivir really a magic bullet for COVID-19, also a coronavirus? In this article, we first overview the general information about SARS-CoV-2 and its potential suppressing drug remdesivir. Then, we carefully discussed the limitation with the remdesivir antiviral study, including the case report by compassionate use of remdesivir. Finally, from the pharmaceutical perspective we explored the anti-virus capability of remdesivir against different viruses to see whether it’s a magic bullet for COVID-19. Therefore, this paper provides crucial evidence and objective theoretical basis on remdesivir to cure COVID-19 infections.